Discovery of 2-[4-{{2-(2<i>S</i>,5<i>R</i>)-2-Cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic Acid (ABT-279):  A Very Potent, Selective, Effective, and Well-Tolerated Inhibitor of Dipeptidyl Peptidase-IV, Useful for the Treatment of Diabetes

Madar, David J.; Kopecka, Hana; Pireh, Daisy; Yong, Hong; Pei, Zhonghua; Li, Xiaofeng; Wiedeman, Paul E.; Djurić, Stevan W.; Geldern, Thomas W von; Fickes, Michael G.; Bhagavatula, Lakshmi; McDermott, Todd S.; Wittenberger, Steven J.; Richards, Steven; Longenecker, K.L.; Stewart, Kent D.; Lübben, Thomas; Ballaron, Stephen J.; Stashko, Michael A.; Long, Michelle A.; Wells, Heidi; Zinker, Bradley A.; Mika, Amanda K.; Beno, David W. A.; Kempf-Grote, Anita J; Polakowski, James S.; Segreti, Jason A.; Reinhart, Glenn A.; Fryer, Ryan M.; Sham, Hing L.; Trevillyan, James M.

doi:10.1021/jm060777o

Cited by 38 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this case, the Ser630 Oγ atom was naturally oriented toward the inhibitor and very close to the inhibitor nitrile C atom (<3 Å, the Oγ atom is colored cyan in Fig. 4e ) (PDB ID: 2AJL [ 42 ], 2G5P, 2G5T, 2G63 [ 33 ], 2I03 [ 43 ], 3BJM (saxagliptin) [ 20 ] and 3W2T (vildagliptin) [ 13 ]). However, for inhibitors that do not require a covalent bond, the Ser630 Oγ atom seems to be oriented in a disorderly manner.…”

Section: Resultsmentioning

confidence: 99%

Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor

et al. 2016

View full text Add to dashboard Cite

BackgroundWe comprehensively analyzed X-ray cocrystal structures of dipeptidyl peptidase IV (DPP-4) and its inhibitor to clarify whether DPP-4 alters its general or partial structure according to the inhibitor used and whether DPP-4 has a common rule for inhibitor binding.ResultsAll the main and side chains in the inhibitor binding area were minimally altered, except for a few side chains, despite binding to inhibitors of various shapes. Some residues (Arg125, Glu205, Glu206, Tyr662 and Asn710) in the area had binding modes to fix a specific atom of inhibitor to a particular spatial position in DPP-4. We found two specific water molecules that were common to 92 DPP-4 structures. The two water molecules were close to many inhibitors, and seemed to play two roles: maintaining the orientation of the Glu205 and Glu206 side chains through a network via the water molecules, and arranging the inhibitor appropriately at the S2 subsite.ConclusionsOur study based on high-quality resources may provide a necessary minimum consensus to help in the discovery of a novel DPP-4 inhibitor that is commercially useful.Electronic supplementary materialThe online version of this article (doi:10.1186/s12900-016-0062-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In their development of DPP-IV inhibitors, Abbott also studied adamantane derivatives like 358 (K i = 62 nM, Scheme 52). 672 Focus of this research was on the modification of the cyanopyrrolidin motif, thereby enhancing selectivity for DPP-IV inhibiton over other enzymes. However, their candidate for clinical development is piperidine derivative 359 (ABT-279).…”

Section: Miscellaneous Non-cns Targetsmentioning

confidence: 99%

The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives

Wanka¹,

Iqbal²,

Schreiner³

2013

Chem. Rev.

564

475

View full text Add to dashboard Cite

“…This approach and other structural modifications, for example, vinyl substitution, resulted in the identification of several lead compounds for further preclinical and clinical evaluation, including vildagliptin (LAF‐237) [37,47], sitagliptin (MK‐0431) [46] and saxagliptin (BMS‐477118) [48,49] (table 1). Numerous other molecules with DPP‐IV inhibitory activity have been synthesized and characterized in vitro [50–52].…”

Section: Synthesis and Early Characterization Of Dpp‐iv Inhibitorsmentioning

confidence: 99%

Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug

Idris¹,

Donnelly²

2007

Diabetes Obesity Metabolism

104

View full text Add to dashboard Cite

Exploiting the incretin effect to develop new glucose-lowering treatments has become the focus of intense research. One successful approach has been the development of oral inhibitors of dipeptidyl peptidase-IV (DPP-IV). These drugs reversibly block DPP-IV-mediated inactivation of incretin hormones, for example, glucagon-like peptide 1 (GLP-1) and also other peptides that have alanine or proline as the penultimate N-terminal amino acid. DPP-IV inhibitors, therefore, increase circulating levels and prolong the biological activity of endogenous GLP-1, but whether this is sufficient to fully explain the substantial reduction in haemoglobin A(1c) (HbA(1c)) and associated metabolic profile remains open to further investigation. DPP-IV inhibitors such as vildagliptin and sitagliptin have been shown to be highly effective antihyperglycaemic agents that augment insulin secretion and reduce glucagon secretion via glucose-dependent mechanisms. This review summarizes the major clinical trials with DPP-IV inhibitors as monotherapy and as add-on therapy in patients with type 2 diabetes. The magnitude of HbA(1c) reduction with DPP-IV inhibitors depends upon the pretreatment HbA(1c) values, but there seems to be no change in body weight, and very low rates of hypoglycaemia and gastrointestinal disturbance with these agents. DPP-IV inhibitors represent a major new class of oral antidiabetic drug and their metabolic profile offers a number of unique clinical advantages for the management of type 2 diabetes.

show abstract

Discovery of 2-[4-{{2-(2S,5R)-2-Cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic Acid (ABT-279): A Very Potent, Selective, Effective, and Well-Tolerated Inhibitor of Dipeptidyl Peptidase-IV, Useful for the Treatment of Diabetes

Cited by 38 publications

References 23 publications

Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor

Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor

The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives

Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug

Contact Info

Product

Resources

About